Format

Send to

Choose Destination
Clin Ophthalmol. 2019 Sep 5;13:1727-1733. doi: 10.2147/OPTH.S225506. eCollection 2019.

Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary.

Author information

1
Physicians Protocol, Greensboro, NC, USA.
2
Science in Vision, Akron, NY, USA.

Abstract

Purpose:

To evaluate the effects of low-level light therapy (LLLT) on the resolution of recalcitrant chalazia.

Patients and Methods:

This was a single-site retrospective chart review of patients with chalazia, all of whom were unresponsive to previous pharmaceutical therapy or surgical intervention, who received a 15 min LLLT treatment in conjunction with a standard pharmaceutical regimen. A second treatment was applied 24 hrs to as late as 2 months if there was no evidence of progression of resolution in appearance.

Results:

A total of 26 eyes of 22 patients with relevant history and treatment were reviewed, all with a history of prior pharmaceutical treatment for their chalazia. After a single 15 min LLLT treatment, followed by a standard pharmaceutical regimen, 46% of eyes (12/26) showed resolution of their chalazia. Resolution was noted from 3 days to one-month post-treatment. With a second treatment, the chalazia resolved in 92% of eyes (24/26). Only two eyes of the 26 (8%) required incision and curettage after LLLT treatment.

Conclusion:

The use of LLLT for the treatment of recalcitrant chalazia appears to be beneficial in patients who have failed topical and/or systemic therapy, significantly reducing the likelihood of requiring surgical intervention.

KEYWORDS:

LLLT; chalazia; chalazion; low level light therapy

Conflict of interest statement

Dr Karl Stonecipher is a consultant to Eyevance, Eyepoint, J and J, Kala, Nidek, Novartis, Presbia, Refocus, Espansione Marketing S.p.A., Alcon, Allergan, and Bausch Health. He reports personal fees from Allergan, Alcon, Espansione, and Bausch Health during the conduct of the study. He also received grants and personal fees from Allergan, Alcon, Bausch Health, Presbia, Refocus, and Espansione, outside the submitted work. He is an employee of TLC. Dr Rick Potvin reports personal fees from Physicians Protocol during the conduct of the study. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center